Dr. Manuel Hidalgo is a highly distinguished physician-scientist serving as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital since 2019. He holds the prestigious Walter B. Wriston Professorship of Pancreatic Cancer Research at Weill Cornell Medicine, reflecting his significant contributions to cancer therapeutics. With medical training completed at the University of Navarra in Pamplona, Spain in 1992 and a doctorate in infectious diseases and cancer from the University Autónoma of Madrid, Spain, Dr. Hidalgo has built an illustrious career spanning multiple continents. His professional journey includes leadership roles at Harvard Medical School as Theodore W. and Evelyn G. Berenson Professor of Medicine, Director of the Rosenberg Clinical Cancer Center at Beth Israel Deaconess Medical Center, and significant positions at the Spanish National Cancer Research Centre in Madrid.
Internationally recognized as an authority on pancreatic cancer, Dr. Hidalgo has published more than 220 articles in top-tier peer-reviewed journals, advancing the field of gastrointestinal oncology and drug development. His translational research program has secured continuous funding from the National Cancer Institute and earned him a prestigious European Research Council advanced grant, demonstrating the significance of his scientific contributions. Dr. Hidalgo's work focuses on developing innovative therapeutic approaches for pancreatic cancer, with particular emphasis on immune treatment strategies that bridge preclinical models and clinical applications. His expertise in early clinical development of new anticancer agents has positioned him as a leading figure in bringing novel treatments from laboratory discovery to patient care, with profound implications for improving outcomes in difficult-to-treat malignancies.
Dr. Hidalgo serves on the Board of Directors for both Bristol Myers Squibb and Guardant Health, bringing his extensive clinical research expertise to shape the future of cancer therapeutics and diagnostics in the pharmaceutical industry. As a dedicated educator, he directs the Vail ASCO-AACR course in clinical cancer research and has supervised numerous PhD students and mentored junior faculty across his career. Under his leadership, Weill Cornell Medicine and NewYork-Presbyterian are working toward achieving National Cancer Institute-designated Comprehensive Cancer Center status, with a focus on expanding access to innovative clinical trials for underserved populations. Dr. Hidalgo remains committed to advancing precision oncology through enhanced translational research infrastructure and collaborative partnerships that accelerate the development and adoption of cutting-edge cancer treatments.
